SCHEMBL4675398

SCHEMBL4675398

N#CCOc1ccc2cc(CNC=O)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH7 P40394 1/20 0.39
SLC2A1 P11166 2/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH2 P05091 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RAD52 P43351 1/20 0.37
PAX8 Q06710 1/20 0.37
FFAR1 O14842 1/20 0.36
RAB9A P51151 1/20 0.35
PPARG P37231 1/20 0.35
CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675400 0.81 NOS1 (0.42) SLC2A1KDM4EALDH1A1SMN1; SMN2ALDH2
SCHEMBL4670146 0.78 NCEH1 (0.40) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL4670306 0.74 ASIC3 (0.44) SLC2A1KDM4EALDH1A1SMN1; SMN2ALDH2
SCHEMBL1999154 0.74 ADH1B (0.59) ADH1BADH1CADH1AADH7FFAR1
SCHEMBL11026671 0.72 AGXT (0.57) KDM4EALDH1A1SMN1; SMN2ALDH2GLA
SCHEMBL4672721 0.71 ADH1B (0.46) ADH1BADH1CADH1AADH7HSD17B10
SCHEMBL6572264 0.70 PTGS2 (0.45) SLC2A1KDM4EALDH1A1SMN1; SMN2ALDH2
SCHEMBL4670561 0.69 ALDH1A1 (0.42) SLC2A1KDM4EALDH1A1SMN1; SMN2ALDH2
SCHEMBL10133340 0.68 HSD17B10 (0.46) KDM4EALDH1A1SMN1; SMN2ALDH2GLA
SCHEMBL18105274 0.67 CYP2A6 (0.48) SLC2A1KDM4EALDH1A1SMN1; SMN2ALDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397341-B1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH CORP (US) 2008-08-06 EP disclosed
EP-1397341-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) Wyeth (US) 2004-03-17 EP disclosed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US disclosed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US disclosed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) SERPINC1, F11, SERPINE1 ADH1B 3159/4885ADH1C 168/4885ADH1A 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.